Aclarion, Inc. (NASDAQ: ACON) The stock surged 157% on Tuesday morning. Commercialization contract with the London Clinic. The London Clinic is the UK’s most prestigious independent private hospital, founded in 1932 and the Spine Clinic was the first UK-based spine specialist in 1997.
“The London Clinic’s focus on delivering the best medical outcomes makes it an ideal customer for Aclarion, which is committed to providing Gnoscan solutions to physicians and patients around the world,” said London Spine. Founder and neurosurgeon Dr. John Sutcliffe said: Clinic. “Our partnership with Aclarion enables London Spine Clinic to continue to provide the high quality care patients have come to expect. Patients require careful assessment, diagnosis and understanding of the various treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with back pain and improve the accuracy of each diagnosis.”
$ACON Aclarion Announces New Partnerships with London Clinic and London Spine Clinic
—TheStockDon (@TheStockDon) May 30, 2023
Learn more about Nociscan technology
Nociscan technology from Aclarion, Inc. is an innovative medical solution aimed at revolutionizing the diagnosis of disc-related diseases. These leverage biomarkers and proprietary augmented intelligence algorithms to help doctors pinpoint the location of chronic back pain.
$ACON Pay attention to volume and running. Aclarion Announces New Partnerships with London Clinic and London Spine Clinic
— David Kang (@realtraderkang) May 30, 2023
Of interest is its advantage compared to the current standard of care. It offers a non-invasive approach and ensures patient comfort and safety. Given that it’s non-invasive, it also means zero radiation exposure (typically associated with traditional discography) and zero pain. Best of all, it integrates seamlessly into standard lumbar spine MRI protocols, making it a convenient and efficient option for healthcare providers.
To discover the inside scoop on ACON, enter your email in the box below and subscribe to Microcapdaily.com today.
Subscribe to our 100% free penny stock newsletter. Something big is about to happen!
.snp-pop-34211 .snp-theme6 { max-width: 600px;} .snp-pop-34211 .snp-theme6 h1 {font-size: 15px;} .snp-pop-34211 .snp-theme6 { color: #19232D;} .snp-pop-34211 .snp-theme6 .snp-field ::-webkit-input-placeholder { color: #19232D;} .snp-pop-34211 .snp-theme6 .snp-field :-moz -placeholder { color: #19232D;} .snp-pop-34211 .snp-theme6 .snp-field :-ms-input-placeholder { color: #19232D;} .snp-pop-34211 .snp-theme6 .snp- Field input { border: 1px solid #19232D;} .snp-pop-34211 .snp-theme6 .snp-field { color: #000000;} .snp-pop-34211 .snp-theme6 { background: #fff;} . snp-pop-34211 .snp-theme6::before { background: #E54E53;} .snp-pop-34211 .snp-theme6::after { border-left: 9px solid #E54E53;} .snp-pop-34211 . snp-theme6 .snp-submit {background-color: #E54E53; border-top: 1px solid #E54E53; border-bottom: 1px solid #E54E53; border-left: 1px solid #E54E53; border-right: 1px solid #E54E53; set 0 1px #E54E53, inset 0 -1px #E54E53; }jQuery(document).ready(function(){ // change text of button element jQuery(“.snp-pop-34211 .snp-theme6 .snp- submit”).html(“Subscribe Now”); }); jQuery( “#snppopup-inline-34211.snp-theme6.snp-form” ).first().append( “
privacy policy. We never share your email with anyone.
” ); jQuery(‘#snp_email’).attr(‘type’, ’email’);
This procedure takes approximately 25-45 minutes and thoroughly assesses the spinal disc without compromising accuracy. Plus, the Nociscan technology offers significant cost savings, with his $1,450 list price making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a major step forward in disc-related diagnostic technology, prioritizing patient health, convenience and affordability.
$ACON Dawn $1.55!! https://t.co/TFb11YeuPU pic.twitter.com/xBvbw1DQ8N
— Tiger Line Trading (@TigerLineTrades) May 30, 2023
nosiscan research
They recently completed a 2-year study of 78 patients at a single center. Success rates for patients following treatment strategies aligned with the discs identified by Nociscan rose to a staggering 85%. This represented a significant improvement of 22% compared to patients who did not consider the insights provided by Nociscan in their treatment strategies.
Aclarion expressed confidence in the results. The results of this trial demonstrate Nociscan’s potential to help physicians successfully treat DLBP. Dr. Matthew Gournette, an orthopedic surgeon and lead author of the study, is an avid supporter of Nosis Scan. (ODI). I strongly believe that Nociscan has the potential to revolutionize the standard of care and help all physicians successfully treat chronic back pain. ”
$ACON Pay attention to volume and running. Aclarion Announces New Partnerships with London Clinic and London Spine Clinic
— David Kang (@realtraderkang) May 30, 2023
It is worth noting that, as the company emphasizes, nocturnal scans were performed on all patients studied, but were not part of the surgical decision-making process.
$ACON 5.9 million floats https://t.co/Ff15RnAMTA
—TheStockDon (@TheStockDon) May 30, 2023
Conclusion
The commercial agreement between Aclarion, Inc. and the prestigious London Clinic represents an important milestone for both parties, offering global visibility, increased revenue and potential for scalability. By integrating Aclarion’s innovative his Nociscan technology, the London Clinic demonstrates its commitment to providing cutting-edge medical care that optimizes patient health and improves clinical outcomes. Additionally, the success of this partnership has the potential to expand Nociscan Technology into other institutions and markets, allowing Aclarion, Inc. to become a global leader in noninvasive medical technology while driving significant revenue growth. prize.
We will keep you updated on ACON as more details become available. Be sure to subscribe to Microcapdaily to find out what’s happening in the market.
Subscribe to our 100% free penny stock newsletter. Something big is about to happen!
.snp-pop-4669 .snp-theme6 {max width: 600px;} .snp-pop-4669 .snp-theme6 h1 {font-size: 15px;} .snp-pop-4669 .snp-theme6 { color: #19232D ;} .snp-pop-4669 .snp-theme6 .snp-field ::-webkit-input-placeholder { color: #19232D;} .snp-pop-4669 .snp-theme6 .snp-field :-moz -placeholder { color: #19232D;} .snp-pop-4669 .snp-theme6 .snp-field :-ms-input-placeholder { color: #19232D;} .snp-pop-4669 .snp-theme6 .snp-field input { border: 1px solid #19232D;} .snp-pop-4669 .snp-theme6 .snp-field { color: #000000;} .snp-pop-4669 .snp-theme6 { background: #fff;} . snp-pop-4669 .snp-theme6::before { background: #E54E53;} .snp-pop-4669 .snp-theme6::after { border-left: 9px solid #E54E53;} .snp-pop-4669 . snp-theme6 .snp-submit {background-color: #E54E53; border-top: 1px solid #E54E53; border-bottom: 1px solid #E54E53; border-left: 1px solid #E54E53; border-right: 1px solid #E54E53; set 0 1px #E54E53, inset 0 -1px #E54E53; }jQuery(document).ready(function(){ // change text of button element jQuery(“.snp-pop-4669 .snp-theme6 .snp- submit”).html(“Subscribe Now”); }); jQuery(‘.snp-field .snp-field’).attr(‘type’, ’email’);
Disclosure: I received no compensation for this article/video. MicroCap Daily is not an investment advisor. This article/video does not provide investment advice. Always do your research and make your own investment decisions or consult your local financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold any securities. This article/video is our opinion and is for informational and educational purposes only and does not constitute investment advice. Past performance is not indicative of future performance.
Image by Alex from Pixabay
Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership first appeared in Micro Cap Daily.
Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership article first appeared in Micro Cap Daily.